Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
08:30 - 09:10 40 mins
Registration
09:10 - 09:20 10 mins
Chairperson’s Opening Remarks
09:20 - 09:50 30 mins
Info
Adenovirus and Viral Vectors for Vaccine Applications and Development
Scalable manufacturing Adenoviral vectors platform technology
  • Qian Ruan - Director of Process Development and Production, PaxVax, USA

Adenoviruses’ ability to be easily genetically modified, their excellent safety profiles, broad tissue tropism, and ability to drive robust, sustained transgene expression made them an excellent platform technology.   PaxVax has been using the safety data of military Ad4/Ad7 and developed an adenovirus platform technology for various vaccines (such as HIV, anthrax, H5N1 flu etc.). PaxVax generated Ad4 and Ad7 based viral vectors in fully GMP characterized A549 cell lines. The developed scalable, disposable platform technology uses serum free suspension A549 cells, expanded in disposable bioreactor, purified with disposable membrane chromatography. The products are either in liquid form for intranasal clinical studies or coated capsules form for the gut delivery.

09:50 - 10:20 30 mins
Info
Adenovirus and Viral Vectors for Vaccine Applications and Development
Challenges in the advancement of Vaccine manufacturing in Developing Countries
  • Lakshmi Khandke - Program Advisor, PATH

There are major challenges in developing vaccines particularly multivalent, due to their manufacturing complexity which include the cost, facilities, technology transfer, regulatory guidance, implementation and sustainability from clinical development to commercial manufacturing.  With an emphasis on developing country vaccine manufacturers and transfer of technology, this presentation describes strategies and approaches to better understand and characterize vaccines using a broad analytical tool-kit for development and transferring robust processes.

10:20 - 10:50 30 mins
Adenovirus and Viral Vectors for Vaccine Applications and Development
Spotlight Presentation
10:50 - 11:30 40 mins
Morning Coffee and Networking
11:30 - 12:00 30 mins
Alternative to Conventional Vaccine Approaches
Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector
  • Sarah Gilbert - Professor of Vaccinology , Jenner Institute, University of Oxford
12:00 - 12:30 30 mins
Alternative to Conventional Vaccine Approaches
High Titre Stable Suspension Lentiviral Vector Producer Cell Lines Using Bacterial Artificial Chromosome (BAC)
  • Mark (Mao Xiang) Chen - Manager, Cell Line Development, Cell and Gene Therapy CMC,, GlaxoSmithKline R&D
12:30 - 13:00 30 mins
Alternative to Conventional Vaccine Approaches
Rapid HeLa based Producer Cell Line Development for Scalable rAAV Production
  • Aubrey R Tiernan - Senior Scientist, Head of Cell Line Development, Ultragenyx Pharmaceuticals, Inc
13:00 - 13:30 30 mins
Alternative to Conventional Vaccine Approaches
Spotlight Presentation
13:30 - 14:45 75 mins
Lunch and Networking
14:45 - 16:15 90 mins
Info
Process Development – Platform Processes for Increased Efficiency and Reduced Risk
Tri Dialogue: Process Development – Platform Processes for Increased Efficiency and Reduced Risk
  • Yan-Ping Yang - Head of BioProcess Research & Development, Sanofi
  • Dieter Palmberger - Senior Scientist, acib - Austrian Centre of Industrial Biotechnology
  • Amish Patel - Senior Director, Product Development, PaxVax

Talk One: Recent challenges and opportunities in Downstream processing

Confirmed speaker: Yan-Ping Yang, Head of Bioprocess Research & Development, North America, Sanofi Pasteur 

Talk 2: Process development for a flexible vaccine vector platform based on recombinant life virus

Confirmed speaker: Dieter Palmberger, Senior Scientist, acib - Austrian Centre of Industrial Biotechnology, Austria

Talk 3: Development of different delivery platforms for Biologics 

  • Unlike conventional formulation development, delivery platform and late stage formulation focus more on the control of delivery technology for dosage forms. Conditions to keep the desired potency of drug/biologic before and during the administration is equally important.
  • Poor delivery platform will causes significant potency loss of drug/biologic during the administration no matter how great of shelf-life the product has.
  • Scientists working in the formulation field should consider the delivery route as a critical factor in developing their product and design the formulation and delivery study to support it or could see failure in the animal study, clinical study and impact the future of the project

Confirmed speaker: Amish Patel, Senior Director, Product Development, PaxVax, USA

16:15 - 16:20 5 mins
Opening of Exhibition Hall & Networking Drinks
08:30 - 09:10

Registration

More
09:10 - 09:20

Chairperson’s Opening Remarks

More
Showing of Streams
10:50 - 11:30

Morning Coffee and Networking

More
Showing of Streams
13:30 - 14:45

Lunch and Networking

More
Showing of Streams
16:15 - 16:20
Opening of Exhibition Hall & Networking Drinks

Opening of Exhibition Hall & Networking Drinks

More